<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BICALUTAMIDE</span><br/>(bi-ca-lu'ta-mide)<br/><span class="topboxtradename">Casodex<br/></span><b>Classifications:</b> <span class="classification">antineoplastics</span>; <span class="classification">antiandrogen</span><br/><b>Prototype: </b>Flutamide<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Bicalutamide is a nonsteroidal antiandrogen. It inhibits the pharmacologic effects of androgen by binding to the androgen
         receptors in the target tissue.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Prostatic carcinoma is androgen sensitive; it responds to removal of the source of androgen or treatment that counteracts
         the effects of androgen.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>In combination with a luteinizing hormone-releasing hormone (LHRH) analog for advanced prostate cancer.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to bicalutamide, pregnancy (category X).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Moderate to severe hepatic impairment; lactation. Safety and efficacy in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Advanced Prostate Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50 mg once/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give drug at the same time each day.</li>
<li>Start treatment with bicalutamide at the same time as treatment with a luteinizing hormone-releasing hormone (LHRH) analog.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, paresthesia, insomnia, anxiety, decreased libido, confusion, neuropathy, somnolence, nervousness, headache. <span class="typehead">CV:</span>
<span class="speceff-common">Hot flashes,</span> hypertension, chest pain, CHF. <span class="typehead">GI:</span>
<span class="speceff-common">Constipation, nausea, diarrhea,</span> vomiting, increased liver function tests, abdominal pain, anorexia, dyspepsia, dry mouth, melena. <span class="typehead">Urogenital:</span> Nocturia, hematuria, UTI, impotence, gynecomastia, incontinence, frequency, dysuria, urinary retention, urgency. <span class="typehead">Metabolic:</span> Peripheral edema, hyperglycemia, weight loss, weight gain, gout. <span class="typehead"> Musculoskeletal:</span> Myasthenia, arthritis, myalgia, leg cramps, pathologic fractures. <span class="typehead">Skin:</span> Rash, sweating, dry skin, pruritus, alopecia. <span class="typehead">Body as a Whole:</span> Flu syndrome, bone pain, infection, anemia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase effects of <span class="classification">oral anticoagulants</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine and feces. <span class="typehead">Half-Life:</span> 5.8 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of disease progression.</li>
<li>Lab tests: Periodic PSA levels, CBC, liver functions, renal functions; with concurrent coumadin therapy, closely monitor PT
            and INR.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report jaundice or any other troubling adverse effects immediately.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>